-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The study, recently published online in Scientific Reports, found that in a mouse model of human type 2 diabetes, Rhodiola reduced fasting blood glucose levels, improved response to insulin injections, and modulated gastric composition of gut bacteria and decreased several biomarkers of inflammatio.
"The prevalence of type 2 diabetes and the associated healthcare costs have risen steadily in recent decade.
The team tested whether Rhodiola rosea could improve glucose homeostasis using a genetically engineered mouse model that develops obesity, insulin resistance and hyperglycemia, similar to advanced human type 2 diabete.
"Our findings suggest that rhododendron may be beneficial in the treatment of type 2 diabetes by altering the action of the microbiota, leading to increased gut barrier integrity and reduced translocation of inflammatory molecules into the circulation," Jafari sai.
The next step for the team is to conduct larger follow-up studies in different mouse models of obesity-induced diabetes to confirm these findings and investigate the underlying molecular mechanism.
"Our study provides a solid case for the importance of conducting high-quality preclinical research based on reliable methods to evaluate the efficacy of standardized botanical extract.
The research team included students and faculty from UC Irvine, UC Irvine Health, and Brigham Young University in Provo, Uta.
Mahtab Jafari, Jasmin Grace Juanson Arabit, Robert Courville, Dara Kiani, John .
